Cuffless Blood Pressure Monitoring: When Will It Actually Work?

Truly calibration-free cuffless blood pressure monitoring that meets clinical accuracy standards is likely 3-5 years away, though partial solutions requiring periodic cuff calibration exist today. The gap between consumer marketing claims and clinical reality remains substantial. Multiple technologies are competing to solve what may be the hardest remaining problem in consumer health sensing: measuring blood pressure continuously, accurately, and without any cuff, from a wrist-worn device.

Blood pressure is arguably the most important vital sign for long-term health. Hypertension affects over one billion people globally and is the leading modifiable risk factor for cardiovascular disease, stroke, and kidney disease. Yet blood pressure measurement has been stuck in the cuff era for over a century. A reliable cuffless alternative would transform hypertension management from periodic clinic snapshots to continuous, actionable monitoring.

This article examines the competing technologies, their fundamental challenges, the key industry players, and a realistic assessment of when cuffless blood pressure will deliver on its promise. For foundational context on the optical sensing technology underlying many of these approaches, see our PPG technology guide.

The Technologies Competing for Cuffless Blood Pressure

Multiple sensing approaches are being pursued for cuffless blood pressure estimation. Each has distinct physical principles, advantages, and limitations.

Pulse Transit Time (PTT)

Pulse transit time measures the delay between the heart's electrical depolarization (detected by ECG) and the arrival of the pulse wave at a peripheral site (detected by PPG). The principle is straightforward: higher blood pressure increases arterial stiffness, which increases pulse wave velocity, which decreases the transit time. By measuring PTT continuously, changes in blood pressure can be inferred.

PTT has the strongest theoretical foundation for cuffless blood pressure and has been studied extensively since the 1990s. Mukkamala et al. (2015) provided a comprehensive review of PTT-based blood pressure estimation, documenting both the promise and the limitations.

The fundamental challenges with PTT are: it requires two sensor locations (ECG at the chest or wrist and PPG at a peripheral site), the relationship between PTT and blood pressure is nonlinear and varies between individuals, and it is sensitive to pre-ejection period (PEP) changes that are unrelated to blood pressure. PEP is the time between the ECG R-wave and aortic valve opening, and it varies with cardiac contractility, which changes independently of blood pressure during exercise, stress, and medication use.

Pulse Wave Velocity (PWV)

PWV is closely related to PTT but measures the speed of the pulse wave along an arterial segment rather than the total transit time from heart to periphery. Some approaches estimate PWV from two PPG sensors at different locations on the same limb, eliminating the need for ECG.

PWV has a more direct physical relationship with blood pressure through the Moens-Korteweg equation, which relates wave velocity to arterial wall stiffness and geometry. However, converting PWV to absolute blood pressure still requires knowledge of individual arterial properties (wall thickness, diameter, elastic modulus) that vary between people and change with age, disease, and medication. For related measurement concepts, see our guide on PPG signal processing.

PPG Morphology Analysis

This approach extracts blood pressure information from the shape of the PPG waveform itself, without requiring a separate ECG or second PPG sensor. Features analyzed include the systolic peak amplitude, diastolic notch position, pulse width, rising slope, dicrotic notch timing, and various ratios between these features.

The appeal of PPG morphology analysis is hardware simplicity: it requires only the existing PPG sensor already present in every smartwatch. The challenge is that the PPG waveform shape is influenced by many factors beyond blood pressure, including heart rate, vascular tone, skin temperature, sensor pressure, hydration status, and autonomic nervous system activity. Extracting blood pressure with clinical accuracy from this multifactorial signal has proven extremely difficult.

Deep learning approaches (CNNs, LSTMs, transformers) trained on large datasets of simultaneous PPG and reference blood pressure measurements have shown promising results in some studies, but performance consistently degrades when tested on new populations not represented in the training data. This generalization failure is the central unsolved problem. For how deep learning applies to related PPG challenges, see our motion artifact removal guide.

Ultrasound-Based Methods

Some companies are developing wearable ultrasound transducers that can measure arterial diameter changes and blood flow velocity, from which blood pressure can be estimated using biomechanical models. Ultrasound offers direct measurement of arterial dynamics rather than relying on surrogate signals.

The advantages are more direct physical measurements and potentially higher accuracy. The challenges are power consumption (ultrasound transducers require significant energy), form factor (miniaturizing ultrasound into a comfortable wearable), and cost. This approach is currently more realistic for medical patches or arm-band devices than for smartwatches.

Tonometry

Applanation tonometry measures the pressure required to flatten a superficial artery (typically the radial artery at the wrist). When the artery is partially compressed, the pressure measured by the tonometer equals the intra-arterial pressure. This is the same principle used in goldmann tonometry for measuring eye pressure.

Wearable tonometry faces the challenge of maintaining consistent sensor positioning over the radial artery during daily wear. Even small shifts in sensor placement relative to the artery can cause large measurement errors. Some designs use sensor arrays to compensate for positional uncertainty, but this adds complexity and cost.

The Calibration Problem

Calibration is the single biggest obstacle to practical cuffless blood pressure. Nearly every cuffless approach requires an initial calibration against a reference cuff measurement to establish the individual's blood-pressure-to-signal relationship. Without calibration, the best these systems can do is detect relative changes (blood pressure went up or down) rather than provide absolute values (your blood pressure is 135/85 mmHg).

The deeper problem is calibration drift. The relationship between the measured signal (PTT, PPG morphology, etc.) and blood pressure changes over time as vascular properties evolve due to:

• Vascular tone changes: Arterial smooth muscle tone varies with autonomic state, temperature, medication, caffeine, and stress, altering the PTT-BP relationship hourly
• Aging and disease progression: Arterial stiffness increases with age and conditions like atherosclerosis, changing the baseline relationship over months to years
• Medication effects: Antihypertensive drugs, vasodilators, and other medications alter vascular properties, potentially invalidating the calibration
• Hydration and diet: Fluid status and sodium intake affect blood volume and vascular compliance
• Positional changes: Arm position relative to the heart changes hydrostatic pressure by approximately 0.7 mmHg per centimeter of height difference

Samsung's Galaxy Watch blood pressure feature addresses this pragmatically by requiring recalibration every four weeks with a traditional cuff. This is a reasonable compromise that acknowledges current technological reality, but it undermines the convenience value proposition. A device that still requires regular cuff measurements is an incremental improvement over existing ambulatory blood pressure monitoring, not the revolution that marketing materials suggest. For perspective on how other vital signs perform in wearables, see our blood oxygen level chart.

Positional Sensitivity and Body Mechanics

Wrist-based blood pressure measurement is fundamentally complicated by the relationship between arm position and blood pressure. When you raise your arm above heart level, arterial pressure at the wrist drops by approximately 7 mmHg for every 10 centimeters of elevation above the heart. When you lower your arm below heart level, pressure increases by the same amount.

During a typical day, arm position varies constantly. Reaching for a shelf, typing at a desk, lying on your side in bed, and gesturing during conversation all change the hydrostatic pressure component at the wrist. These positional variations can easily exceed 15-20 mmHg, which is larger than the clinical significance threshold for blood pressure management decisions.

Accelerometer and gyroscope data can estimate arm position to partially compensate for this effect, but the compensation is imperfect. The precise height difference between the wrist sensor and the heart depends on posture, body habitus, and arm angle, none of which are measured with sufficient precision by wrist-mounted inertial sensors. This remains an active research challenge for all wrist-based cuffless blood pressure approaches.

Individual Variability: Why One Model Does Not Fit All

Perhaps the most fundamental challenge for cuffless blood pressure is individual physiological variability. The relationship between any surrogate signal and blood pressure varies substantially between people due to differences in:

• Arterial stiffness (determined by genetics, age, disease state, and lifestyle)
• Arterial geometry (diameter, wall thickness, branching patterns)
• Body composition (subcutaneous fat thickness at the measurement site)
• Skin properties (pigmentation, thickness, moisture, affecting PPG signal quality)
• Cardiovascular dynamics (stroke volume, cardiac output, peripheral resistance)

Population-level models trained on aggregate data inevitably smooth over these individual differences, producing large errors for individuals whose physiology deviates from the population mean. Personalized models (calibrated to the individual) perform better but require the reference measurements that cuffless technology aims to eliminate.

This is the catch-22 of cuffless blood pressure: the technology works best when calibrated to the individual, but calibration requires the very cuff measurement the technology is trying to replace. Breaking out of this cycle requires either dramatically more sophisticated sensing (measuring enough physiological parameters to resolve individual variability from the data alone) or fundamentally new measurement physics. For a parallel challenge in wearable accuracy, see how skin tone affects PPG wavelength selection.

Regulatory Hurdles: AAMI/ISO 81060-2

The regulatory standard for validating blood pressure measurement devices is ISO 81060-2 (equivalent to the AAMI/ANSI standard). This standard specifies that for a device to be clinically validated, it must demonstrate:

• Mean error within plus or minus 5 mmHg compared to reference (invasive arterial line or auscultatory cuff)
• Standard deviation of error within 8 mmHg
• Testing on a minimum of 85 subjects spanning a defined range of blood pressures, ages, and arm circumferences

These requirements were designed for cuff-based devices and present particular challenges for cuffless technology. The accuracy thresholds are tight relative to the inherent variability of cuffless methods. The requirement for accuracy across a diverse population is difficult for methods that work best with individual calibration. And the testing protocol (typically sequential measurements in a controlled clinical setting) may not reflect real-world wearable use where posture, motion, and environment vary.

Regulators including the FDA and European notified bodies are actively developing new guidance specific to cuffless blood pressure devices, recognizing that the existing cuff-device standard may not be perfectly applicable. However, there is broad consensus that any cuffless device intended for clinical use must demonstrate accuracy comparable to existing validated methods. The bar remains high, appropriately so given the clinical consequences of inaccurate blood pressure measurement.

Key Industry Players and Their Approaches

Samsung

Samsung's Galaxy Watch blood pressure feature uses PPG morphology analysis with mandatory cuff calibration every four weeks. It has regulatory clearance in South Korea and several other countries but has not received FDA clearance for the US market as of early 2026. Samsung's approach is pragmatic: acknowledge the calibration requirement and deliver a partial solution today rather than waiting for the calibration-free ideal.

Aktiia

Aktiia offers a wrist-worn device specifically designed for blood pressure monitoring (not a general-purpose smartwatch). It uses an optical sensor with a proprietary algorithm and requires initial calibration with a cuff. Aktiia has CE marking in Europe and has published validation data showing performance approaching (though not consistently meeting) ISO 81060-2 requirements. Their focus on blood pressure as the primary use case allows hardware optimization that general-purpose smartwatches cannot match.

Biobeat

Biobeat produces a medical-grade disposable chest patch and a wristwatch device for continuous cuffless blood pressure monitoring, primarily for clinical and remote patient monitoring applications. Their technology combines PPG with additional sensors and has FDA 510(k) clearance for specific clinical use cases. Biobeat targets healthcare settings rather than direct-to-consumer markets. For how Biobeat compares with other clinical-grade devices, see our wearable health device guide.

Valencell

Valencell has developed biometric sensor technology used in multiple third-party devices and has published data on calibration-free blood pressure estimation using PPG. Their approach leverages large training datasets and proprietary signal processing to attempt population-level blood pressure estimation without individual calibration. Valencell's technology is typically integrated into third-party devices rather than sold directly to consumers.

Other Players

Numerous startups and established medical device companies are pursuing cuffless blood pressure, including Leman Micro Devices, Blumio (ultrasound-based), and research groups at institutions worldwide. Apple has filed extensive patent portfolios related to blood pressure measurement, though no product feature has been announced. Google/Fitbit is widely reported to be developing blood pressure capabilities for Pixel Watch. The competitive intensity suggests significant commercial potential, but also highlights that no one has solved the fundamental technical challenges convincingly.

Realistic Timeline Assessment

Based on the current state of technology, regulatory requirements, and industry progress, here is a realistic assessment of the cuffless blood pressure timeline:

Available now (2025-2026): Devices requiring periodic cuff calibration that provide trending data and relative change detection. Clinically useful for some patients as a supplement to traditional monitoring, but not a replacement. Samsung Galaxy Watch and Aktiia are the leading examples.

Near-term (2027-2028): Improved algorithms and multi-sensor fusion (PPG plus additional modalities) may extend calibration intervals from weeks to months. Apple is likely to introduce a blood pressure feature requiring infrequent calibration. Accuracy during daily wear will improve but likely still fall short of ISO 81060-2 across all populations.

Medium-term (2028-2030): Truly calibration-free devices may achieve regulatory clearance for specific populations (e.g., healthy adults without vascular disease) and specific use cases (trend monitoring, screening for hypertension). Full clinical accuracy across all populations without any calibration remains uncertain.

Long-term (2030+): Novel sensing modalities (wearable ultrasound, multi-spectral optical sensing, bioimpedance integration) may eventually enable clinical-grade cuffless blood pressure for general use. The timeline depends heavily on breakthrough innovations that cannot be reliably predicted.

The honest assessment is that cuffless blood pressure will arrive gradually, not as a sudden revolution. Each incremental improvement will expand the clinical utility, but replacing the traditional cuff entirely for all medical applications is a substantially harder problem than the industry's marketing suggests. For consumers tracking cardiovascular health today, combining periodic cuff measurements with wearable trend data from devices like those in our wearable comparison guides provides the most complete picture.

What Consumers Should Do Today

If you are interested in blood pressure monitoring, the practical recommendations are:

1. Do not rely on any current wearable as your sole blood pressure measurement method. Use a validated upper-arm cuff (look for AAMI/ISO 81060-2 validation) for baseline and periodic measurements.
2. If using a cuffless device like Samsung Galaxy Watch, follow the calibration schedule strictly and understand that readings are most useful for detecting trends and changes, not for precise absolute values.
3. Measure blood pressure at consistent times and positions (seated, arm supported at heart level, after five minutes of rest) for the most meaningful comparisons over time.
4. Share your data with your healthcare provider rather than making independent medication decisions based on wearable readings.
5. Stay informed about new device releases and FDA clearances, as the field is advancing rapidly and clinically validated devices will become available incrementally.

For those monitoring other cardiovascular metrics alongside blood pressure, understanding how wearables detect atrial fibrillation provides complementary context on the capabilities and limitations of consumer cardiac monitoring.

Frequently Asked Questions

Can the Samsung Galaxy Watch accurately measure blood pressure?

The Samsung Galaxy Watch (Series 3 and later with the Samsung Health Monitor app) can measure blood pressure, but with important caveats. It requires calibration against a traditional cuff every four weeks, it is currently available only in select countries with regulatory clearance, and its accuracy is best for tracking relative changes rather than providing absolute blood pressure values. Independent validation studies show mean errors of 3-8 mmHg for systolic and 3-6 mmHg for diastolic pressure under controlled conditions, which is at the boundary of clinical acceptability per AAMI standards.

Why is cuffless blood pressure so hard to get right?

Cuffless blood pressure faces fundamental challenges that make it exceptionally difficult. Blood pressure varies continuously (by 20-30 mmHg or more throughout a day) based on activity, posture, stress, hydration, and vascular tone. The surrogate signals used by cuffless methods (pulse transit time, PPG waveform morphology) correlate with blood pressure but are also affected by many confounding factors. Calibration drifts over days to weeks as vascular properties change. Individual physiological variability means one-size-fits-all models perform poorly, and personalized models require frequent recalibration with a cuff, undermining the convenience benefit.

When will a truly cuffless blood pressure device be FDA-approved?

Partial cuffless solutions requiring periodic cuff calibration are already available (Samsung Galaxy Watch in some markets, Aktiia). A truly calibration-free cuffless blood pressure device meeting the full FDA clearance standard for clinical accuracy is estimated to be 3-5 years away as of early 2026. The major barriers are not the sensing technology itself but demonstrating sufficient accuracy across diverse populations without individual calibration, and meeting the stringent ISO 81060-2 validation standard that regulators require.

Is cuffless blood pressure accurate enough for medical decisions?

Currently, no. No cuffless blood pressure device on the market meets the accuracy requirements of ISO 81060-2 (mean error within 5 mmHg, standard deviation within 8 mmHg) without periodic cuff calibration. Even with calibration, accuracy degrades over days to weeks. For clinical decisions such as initiating or adjusting antihypertensive medication, traditional cuff-based measurements or ambulatory blood pressure monitoring (ABPM) remain the standard of care. Cuffless devices are best used for trend monitoring and lifestyle feedback, not for clinical blood pressure management.